April 26, 2026Journal of the American College of Cardiology165 citations
View Full PaperTranscatheter Mitral Valve Therapy in the United States
Key Result
Transcatheter edge-to-edge repair (TEER) and transcatheter mitral valve replacement volumes increased from 2014 to 2019, with TEER 30-day mortality decreasing from 5.6% to 4.1%.
Key Points
- To evaluate trends in procedure volumes and outcomes of transcatheter mitral valve therapies in the U.S. over six years.
- Data from the STS/ACC Transcatheter Valve Therapy Registry, including 37,475 patients undergoing TEER and TMVR, from 2014 to 2020.
- Analysis of annual procedure volumes and mortality rates for TEER and TMVR procedures.
- TEER procedure volume increased from 1,152 to 10,460 annually from 2014 to 2019.
- 30-day mortality rates for TEER decreased from 5.6% to 4.1%, while 1-year mortality rates fell from 27.4% to 22.0%.
- Early TMVR use led to FDA approval in 2017; the 2019 30-day mortality rate was reported at 3.9%.
Study Design
Type
Observational (n=37,475)
Multicenter
Yes
Structured PICO
P
Population
37,475 patients undergoing a mitral transcatheter procedure (33,878 TEER and 3,597 TMVR) in the United States between 2014 and March 31, 2020.
I
Intervention
Transcatheter edge-to-edge repair (TEER) and transcatheter mitral valve replacement (TMVR) with an approved device.
O
Outcome
Mortality rates at 30 days and 1 year, and annual procedure volumes.hard clinical
Real-world registry data from the US demonstrates a rapid increase in transcatheter mitral valve procedure volumes from 2014 to 2020, accompanied by decreasing 30-day and 1-year mortality rates.
Abstract
Data for nearly all patients undergoing transcatheter edge-to-edge repair (TEER) and transcatheter mitral valve replacement (TMVR) with an approved device in the United States is captured in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. All data submitted for TEER or TMVR between 2014 and March 31, 2020, are reported. A total of 37,475 patients underwent a mitral transcatheter procedure, including 33,878 TEER and 3,597 TMVR. Annual procedure volumes for TEER have increased from 1,152 per year in 2014 to 10,460 per year in 2019 at 403 sites and for TMVR from 84 per year to 1,120 per year at 301 centers. Mortality rates have decreased for TEER at 30 days (5.6%-4.1%) and 1 year (27.4%-22.0%). Early off-label use data on TMVR in mitral valve-in-valve therapy led to approval by the U.S. Food and Drug Administration in 2017, and the 2019 30-day mortality rate was 3.9%. Overall improvements in outcomes over the last 6 years are apparent. (STS/ACC TVT Registry Mitral Module; NCT02245763).
Cite This Study
Mack et al. (Mon,) conducted a observational in Mitral valve disease (n=37,475). Transcatheter edge-to-edge repair (TEER) and transcatheter mitral valve replacement (TMVR) was evaluated on Mortality rates at 30 days and 1 year. Transcatheter edge-to-edge repair (TEER) and transcatheter mitral valve replacement volumes increased from 2014 to 2019, with TEER 30-day mortality decreasing from 5.6% to 4.1%.